Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...
Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies revealed in an SEC ...
More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results